scispace - formally typeset
C

Charles M. Perou

Researcher at University of North Carolina at Chapel Hill

Publications -  645
Citations -  235604

Charles M. Perou is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 156, co-authored 573 publications receiving 202951 citations. Previous affiliations of Charles M. Perou include North Carolina Central University & University of Chicago.

Papers
More filters
Journal ArticleDOI

Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.

TL;DR: The results presented here help to improve the understanding of the wide range of breast cancer cell line models through the appropriate pairing of cell lines with relevant in vivo tumor and normal cell counterparts.
Journal ArticleDOI

Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts.

TL;DR: This study of murine models of breast carcinoma encompasses the largest comprehensive genomic dataset to date to identify human-to-mouse disease subtype counterparts and indicates that multiple genetically engineered mouse models are needed to represent the diversity of human breast cancers.
Journal ArticleDOI

A compact VEGF signature associated with distant metastases and poor outcomes

TL;DR: This signature suggests that the response to hypoxia includes the ability to promote new blood and lymphatic vessel formation, and that the dual targeting of multiple cell types and pathways will be needed to prevent metastatic spread.
Journal ArticleDOI

Cell-Type-Specific Responses to Chemotherapeutics in Breast Cancer

TL;DR: In vivo data corroborated the cell-type-specific responses to chemotherapeutics observed in vitro, including the induction of p21waf1, and similarities between in vivo and in vitro responses help to identify important response mechanisms to chemtherapeutics.